FDA Approves Secukinumab as First IL-17 Biologic for Polymyalgia Rheumatica

The FDA approved Novartis' secukinumab (Cosentyx) 150 mg for polymyalgia rheumatica (PMR) in adults with inadequate corticosteroid response. The approval follows phase 3 trial results showing sustained remission in 40.5% of patients vs. 20.5% on placebo. Secukinumab is the first IL-17 biologic approved for PMR, offering a new treatment option with a steroid-sparing effect.

Original reporting
Published Nov 17, 2026, 3:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 7:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
FDA Approves Secukinumab as First IL-17 Biologic for Polymyalgia Rheumatica — source image
Decision brief

The 30-second read

$NVSBullishMed
01

Why it matters

The FDA approval of secukinumab 150 mg for steroid-inadequate or steroid-intolerant PMR patients introduces a new mechanism (IL-17A inhibition) and provides trial-backed sustained remission and steroid-sparing data, but with notable infection-related safety considerations.

02

Market read

Traders can treat this as a same-day label expansion catalyst for Novartis’s Cosentyx, with quantifiable efficacy and safety details that affect near-term sentiment and longer-term commercial modeling.

03

What to watch

Real-world uptake will depend on clinician comfort with infection screening/vaccination protocols and payer reimbursement for biologics in PMR, especially given the steroid-taper context.

Relevance 7/10Novelty 9/10Timing: FDA approval announced Nov. 17, 2026, same-day headline catalyst.

Background

PMR is a steroid-dependent inflammatory condition in adults 50+, with relapse during taper driving prolonged glucocorticoid exposure and associated risks.

Company-level read

Ticker impact

$NVSBullishMedium confidence
Context

FDA approved secukinumab (Cosentyx) 150 mg for polymyalgia rheumatica, making it the first IL-17 biologic approved for this indication.

Expected impact

Likely positive repricing as investors model new PMR uptake and reduced reliance on corticosteroids.

Evidence & confidence

The article is a direct FDA approval with specific efficacy and safety outcomes, which is typically material for the branded drug’s commercial outlook.

Market effects

Reinforces IL-17 biologics’ expanding role in inflammatory rheumatology and may intensify competitive positioning versus existing IL-6 pathway options.

Primarily US regulatory-driven demand expectations for a globally marketed biologic.

Could accelerate global uptake discussions and payer coverage planning for PMR beyond the US.

Counterpoint

Infection and hypersensitivity signals (UTIs, cryptococcal meningitis) could limit real-world adoption versus corticosteroids or IL-6 options, tempering commercial upside.

Key entities

  • secukinumab

    Cosentyx IL-17A biologic approved for PMR at 150 mg in steroid-inadequate or steroid-taper-intolerant adults.

  • Cosentyx

    Novartis-branded secukinumab; first FDA-approved IL-17 biologic for PMR per the article.

  • REPLENISH trial

    Phase 3 randomized, double-blind, placebo-controlled study in recently relapsed PMR; sustained remission and steroid exposure outcomes reported.

  • FDA

    Approved secukinumab 150 mg for PMR on Nov. 17, 2026.

Related articles

$NVSMed

FDA Approves Secukinumab as First Anti–IL-17 Biologic for PMR

The FDA approved a 150-mg dose of secukinumab (Cosentyx, Novartis) for polymyalgia rheumatica (PMR), making it the first anti-IL-17 biologic for this condition. The approval was based on the phase 3 REPLENISH trial, which showed higher remission rates with secukinumab plus a glucocorticoid taper compared to the taper alone. According to Novartis, this is the 11th US indication for secukinumab.

$NVSMed

Cosentyx Wins FDA Approval for Polymyalgia Rheumatica Patients Who Cannot Taper Steroids, Doubling Sustained Remission in Trial

Novartis' Cosentyx (secukinumab) 150 mg received FDA approval for polymyalgia rheumatica in patients who cannot taper steroids. The approval follows a trial where 40.5% of patients on Cosentyx achieved sustained remission at one year, compared to 20.5% on placebo. Cosentyx is the first IL-17 blocking biologic approved for this condition, according to Novartis.

$NVSMed

Novartis reports positive phase 3 data on ianalumab for Sjögren’s

Novartis reported positive long-term phase 3 data for ianalumab in Sjögren’s disease, showing improved disease activity and a favorable safety profile. The FDA granted Breakthrough Therapy Designation in January, with a decision expected this year. Ianalumab is also being investigated for other autoimmune diseases. Novartis aims to address the unmet need for disease-modifying treatments in Sjögren’s.

$NVSMed

FDA Clears Secukinumab for Use in Polymyalgia Rheumatica

The FDA approved Novartis' secukinumab (Cosentyx) for treating polymyalgia rheumatica (PMR) in adults unresponsive to corticosteroids. The approval follows positive phase 3 REPLENISH trial results, showing sustained remission rates of 41.2% and 40.6% for 300 mg and 150 mg doses, respectively, compared to 20.4% for placebo. Secukinumab is already approved for several other inflammatory conditions.